Researchers define target and mechanism of antibacterial drug fidaxomicin (dificid)
(Rutgers University) A team of Rutgers University and international scientists has determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid). Fidaxomicin was approved in 2011 for treatment of the CDC 'urgent threat' bacterial pathogen Clostridium difficile (C. diff) and currently is one of two front-line drugs for treatment of C. diff. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 29, 2018 Category: Infectious Diseases Source Type: news
Medication Exposure and Risk of Recurrent C. diff Infection Medication Exposure and Risk of Recurrent C. diff Infection
How does exposure to medications such as antibiotics, corticosteroids, and acid-reducers impact the risk of recurrent C. difficile infection? Does risk differ according to living environment?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 28, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
A moveable feast: Antibiotics give C. diff a nutrient-rich environment, no competition
(North Carolina State University) Using a mouse model, researchers from North Carolina State University have found that antibiotic use creates a " banquet " for Clostridium difficile (C. diff), by altering the native gut bacteria that would normally compete with C. diff for nutrients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 28, 2018 Category: International Medicine & Public Health Source Type: news
Machine learning model provides rapid prediction of C. difficile infection risk
(Massachusetts General Hospital) Investigators from Massachusetts General Hospital, the University of Michigan and Massachusetts Institute of Technology have developed investigational 'machine learning' models, specifically tailored to individual institutions, that can predict a patient's risk of developing C. difficile much earlier than it would be diagnosed with current methods. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 26, 2018 Category: Infectious Diseases Source Type: news
Metabolite therapy proves effective in treating C. difficile in mice
FINDINGSA team of UCLA researchers found that a metabolite therapy was effective in mice for treating a serious infection of the colon known as Clostridium difficile infection, or C. difficile. Mice that were infected with C. difficile were treated with an experimental drug called CSA13, which increased levels of four protective metabolites — molecules that help fuel, maintain and mediate cells. Compared with mice that did not receive CSA13, the mice treated with the drug were significantly more likely to survive the infection, had lower rates of weight loss and — after the treatment was stopped — were less likely ...
Source: UCLA Newsroom: Health Sciences - March 20, 2018 Category: Universities & Medical Training Source Type: news
